Focus Partners Wealth
IONS icon

Focus Partners Wealth’s Ionis Pharmaceuticals IONS Stock Holding History

Focus Partners Wealth’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.4M Sell
165,544
-16,273
-9% -$1.28M 0.01% 648
2025
Q4 		$14.4M Buy
+181,817
New +$13.7M 0.02% 577
2025
Q3 		– Sell
-10,056
Closed -$397K – 2257
2025
Q2 		$397K Buy
10,056
+224
+2% +$7.33K ﹤0.01% 1552
2025
Q1 		$297K Buy
9,832
+1,777
+22% +$58.2K ﹤0.01% 1579
2024
Q4 		$282K Buy
8,055
+2,359
+41% +$88.2K ﹤0.01% 1579
2024
Q3 		$228K Buy
+5,696
New +$265K ﹤0.01% 1411

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Focus Partners Wealth's IONS Position: Q1 2026 in Review

Focus Partners Wealth reduced its Ionis Pharmaceuticals (IONS) stake by 9% in Q1 2026, selling an estimated $1.28M and leaving 165,544 shares worth $12.4M. The position accounts for 0.01% of the portfolio, ranked #648.

Focus Partners Wealth first reported a position in IONS in Q3 2024 and has held it in 6 quarters since. The position peaked at $14.4M in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

  • Focus Partners Wealth held 165,544 shares of Ionis Pharmaceuticals worth $12.4M as of Q1 2026.
  • Focus Partners Wealth sold 16,273 Ionis Pharmaceuticals shares in Q1 2026, an estimated $1.28M.
  • Ionis Pharmaceuticals made up 0.01% of Focus Partners Wealth's portfolio in Q1 2026, its #648 holding.
  • Focus Partners Wealth first reported a position in Ionis Pharmaceuticals in Q3 2024 and has held it in 6 quarters since.
  • Focus Partners Wealth's Ionis Pharmaceuticals position peaked at $14.4M in Q4 2025.
  • 493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Focus Partners Wealth's 13F filing for Q1 2026, filed 15 May 2026.